Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer

Molecular Endocrinology

Volumn 26, Issue 8, 2012, Pages 1443-1454

  Jeong, Yangsik ^a   Xie, Yang ^c   Lee, Woochang ^b   Bookout, Angie L ^c,d   Girard, Luc ^c,d,e   Raso, Gabriela ^f   Behrens, Carmen ^f   Wistuba, Ignacio I ^f   Gadzar, Adi F ^d,e   Minna, John D ^c,d,e   Mangelsdorf, David J ^c,d  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Hamon Center for Therapeutic Oncology Research   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR MARKER; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER INHIBITION; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; ROC CURVE; SMALL CELL LUNG CARCINOMA; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864458911     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1382     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E 2010 Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M 2001 Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98:13790-13795
3. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X 2009 Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 30:121-129
4. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG 2006 Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466-7472
5. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, Sridhar S, Beamis J, Lamb C, Anderson T, Gerry N, Keane J, Lenburg ME, Brody JS 2007 Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13:361-366
6. Wójcik E, Kulpa JK, Sas-Korczyska B, Korzeniowski S, Jakubowicz J 2008 ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 28:3027-3033
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
8. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
9. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ 2006 Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799
10. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870
11. Barish GD, Evans RM 2004 PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158-165
12. Evans RM, Barish GD, Wang YX 2004 PPARs and the complex journey to obesity. Nat Med 10:355-361
13. Mansure JJ, Nassim R, Kassouf W 2009 Peroxisome proliferator-activated receptor in bladder cancer: a promising therapeutic target. Cancer Biol Ther 8:6-15
14. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339
15. Miyamoto H, Messing EM, Chang C 2004 Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61:332-353
16. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF 2000 Promoter methylation and silencing of the retinoic acid receptor-β; gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307
17. Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ, Martinez ED 2010 Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endocrinol 24:1287-1296
18. Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, Vinh-Hung V, Soria JC, Vlastos G, Rapiti E 2011 Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 117:1288-1295
19. www.clinicaltrials.gov
20. Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba, II, Minna JD, Mangelsdorf DJ 2010 Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med 7:e1000378
21. Xie CQ, Jeong Y, Fu M, Bookout AL, Garcia-Barrio MT, Sun T, Kim BH, Xie Y, Root S, Zhang J, Xu RH, Chen YE, Mangelsdorf DJ 2009 Expression profiling of nuclear receptors in human and mouse embryonic stem cells. Mol Endocrinol 23:724-733
22. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD 2006 Multiple oncogenic changes [K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase] are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66:2116-2128
23. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD 2004 Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64:9027-9034
24. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, Mc-Clintock PR, Linnoila RI, Matthews MJ, Bunn Jr PA, Carney D, Minna JD, Mulshine JL 1996 NCI-navy medical oncology branch cell line data base. J Cell Biochem Suppl 24:32-91
25. Townsend EA, Miller VM, Prakash YS 2012 Sex differences and sex steroids in lung health and disease. Endocr Rev 33:1-47
26. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II 2009 Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15:5359-5368
27. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ 2004 Peroxisome proliferator-activated receptoractivation inhibits tumor progression in nonsmall-cell lung cancer. Oncogene 23:100-108
28. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC 2003 Apoptotic action of 17β;-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95:1586-1597
29. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC 2003 Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifenstimulated breast cancer. J Natl Cancer Inst 95:1597-1608
30. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, André J, Chantepie J, Nicolas B, Panaye G 2000 Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 73:237-249
31. Umekita Y, Hiipakka RA, Kokontis JM, Liao S 1996 Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93:11802-11807
32. Allred CD, Kilgore MW 2005 Selective activation of PPAR in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235: 21-29
33. Okamoto M, Lee C, Oyasu R 1997 Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6. Endocrinology 138:5071-5074
34. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM 2007 Synergy between PPAR ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406
35. Wada T, Gao J, Xie W 2009 PXR and CAR in energy metabolism. Trends Endocrinol Metab 20:273-279
36. Fruchart JC 2009 Peroxisome proliferator-activated receptor-(PPAR): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205:1-8
37. Takahashi N, Goto T, Hirai S, Uemura T, Kawada T 2009 Genome science of lipid metabolism and obesity. Forum Nutr 61:25-38
38. Ondrey F 2009 Peroxisome proliferator-activated receptor path-way targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15:2-8
39. Shimizu M, Takai K, Moriwaki H 2009 Strategy and echanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100:369-374
40. Jordan VC 2008 Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44:30-38
41. Aquilina JW, Lipsky JJ, Bostwick DG 1997 Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst 89:689-696
42. Jordan VC 2009 A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69:1243-1254
43. Labrie F, Belanger A, Simard J, Labrie C, Dupont A 1993 Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71:1059-1067
44. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ 2000 Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507-515
45. Seol W, Hanstein B, Brown M, Moore DD 1998 Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol Endocrinol 12:1551-1557
46. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD 2006 A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3:e486
47. Tanaka T, Takeno T, Watanabe Y, Uchiyama Y, Murakami T, Yamashita H, Suzuki A, Aoi R, Iwanari H, Jiang SY, Naito M, Tachibana K, Doi T, Shulman AI, Mangelsdorf DJ, Reiter R, Auwerx J, Hamakubo T, Kodama T 2002 The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). J Atheroscler Thromb 9:233-242
48. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF 2006 High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol Chapter 15:Unit 15:18
49. Bolstad BM, Irizarry RA, Astrand M, Speed TP 2003 A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193
50. Zhu J, Hastie T 2004 Classification of gene microarrays by penalized logistic regression. Biostatistics 5:427-443